Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Non-Current Liabilities (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Other Non-Current Liabilities for 10 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 6647.06% to $1.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 billion, a 6647.06% increase, with the full-year FY2025 number at $1.1 billion, up 6647.06% from a year prior.
  • Other Non-Current Liabilities was $1.1 billion for Q4 2025 at Ultragenyx Pharmaceutical, up from $763.7 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $1.1 billion in Q4 2025 to a low of $471000.0 in Q3 2021.
  • A 5-year average of $324.1 million and a median of $17.1 million in 2025 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: tumbled 99.86% in 2021, then skyrocketed 182928.24% in 2022.
  • Ultragenyx Pharmaceutical's Other Non-Current Liabilities stood at $1.0 million in 2021, then surged by 379.6% to $4.8 million in 2022, then surged by 17790.56% to $862.3 million in 2023, then tumbled by 98.03% to $17.0 million in 2024, then soared by 6647.06% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for RARE's Other Non-Current Liabilities are $1.1 billion (Q4 2025), $763.7 million (Q3 2025), and $17.4 million (Q2 2025).